|Videos|September 11, 2016

How Close Are We to Finding a Cure for HIV?

David Rosenthal, DO, PhD, medical director for the Center for Young Adult, Adolescent and Pediatric HIV Care at Northwell Health, discusses how close researchers are to finding a cure for HIV.

David Rosenthal, DO, PhD, medical director for the Center for Young Adult, Adolescent and Pediatric HIV Care at Northwell Health, discusses how close researchers are to finding a cure for HIV.

Interview Transcript (slightly modified for readability)

“[The National Institute of Health (NIH) has] been increasing the funding and decreasing the funding for many, many years, and so, [when it comes to the question of] how close it is? I don’t know. I believe in the work that Anthony Fauci is doing and I think that the NIH is certainly getting much closer than we were. I think that 2015 was a very good year for HIV cure and HIV prevention in ways we haven’t seen in previous years due to several new breakthroughs in clinical trials.

I’m not a soothsayer; I can’t tell you exactly when it’s going to happen. I think that we’re getting closer than we were, but just like we’ve been working for many, many years for diseases like cancer, and finding a cure for cancer, a vaccine for cancer, we haven’t been fully effective in doing that for many cancers. We still aren’t quite there yet for HIV; I think we have some work still to do, so I’m not expecting something to happen in the coming year but I also don’t think that it’s going to be 50 years from now when we’re going to have some answers.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.